Status:
COMPLETED
Investigating the Pharmacokinetic Properties of NN1250 in Healthy Chinese Subjects
Lead Sponsor:
Novo Nordisk A/S
Conditions:
Diabetes
Healthy
Eligibility:
All Genders
18-45 years
Phase:
PHASE1
Brief Summary
This trial was conducted in Asia. The aim of this trial was to investigate the pharmacokinetic properties (the effect of the investigated drug on the body) of NN1250 (insulin degludec) in healthy Chin...
Eligibility Criteria
Inclusion
- Male or female Chinese subject aged 18-45 years (both inclusive)
- Considered generally healthy upon completion of medical history, physical examination, vital signs and electrocardiogram (ECG), as judged by the Investigator
- Body mass index 19.0-24.0 kg/m\^2 (both inclusive)
Exclusion
- A history of any illness that, in the opinion of the Investigator, might confound the results of the trial or pose risk in administering the trial product to the subject
- Subject who has donated any blood or plasma in the past month or more than 400 mL within 3 months prior to screening
- Not able or willing to refrain from smoking during the inpatient period
Key Trial Info
Start Date :
September 6 2011
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
November 22 2011
Estimated Enrollment :
24 Patients enrolled
Trial Details
Trial ID
NCT01437592
Start Date
September 6 2011
End Date
November 22 2011
Last Update
May 30 2019
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Novo Nordisk Investigational Site
Beijing, Beijing Municipality, China, 100032